Interferon-α/peginterferon-α

Reactions 1467, p22 - 31 Aug 2013 S Interferon-α/peginterferon-α Parkinson’s disease: 2 case reports Two patients developed Parkinson’s disease while receiving interferon-α or peginterferon-α for hepatitis C. A 51-year-old man with hepatitis C developed intermittent tremor while receiving a 36-week course of amantadine, ribavirin and peginterferon-α [route, dosage and time to onset not stated]. His tremor disappeared on completion of the course. Three years later, he developed bradykinesia, asymmetrical/unilateral tremor and rigidity compatible with Parkinson’s disease. He was treated with amantadine, rasagiline and pramipexole [outcome not stated]. A 71-year-old man developed tremor after 8 weeks of interferon-α therapy [route and dosage not stated] for hepatitis C. His tremor resolved on completion of 48 weeks’ therapy. He was commenced on ribavirin and peginterferon-α [route and dosage not stated] 2 years later due to treatment failure, with tremor, bradykinesia and rigidity appearing after 24 weeks. His Parkinson’s disease progressed over 2 years, requiring treatment with levodopa/carbidopa [outcome not stated]. Author comment: "The association of [interferon-α] and [Parkinson’s disease] is important clinically and pathobiologically". Wangensteen KJ, et al. Interferon alpha treatment, hepatitis C and Parkinson's disease. Movement Disorders 28: S295-S296, Jun 2013. Available from: URL: http://dx.doi.org/10.1002/mds.25605 - USA 803092058 1 Reactions 31 Aug 2013 No. 1467 0114-9954/13/1467-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved

Upload
voanh
Category

Documents
view
212
download
0

Embed Size (px):

Transcript of Interferon-α/peginterferon-α

Reactions 1467, p22 - 31 Aug 2013

SInterferon-α/peginterferon-αParkinson’s disease: 2 case reports

Two patients developed Parkinson’s disease while receivinginterferon-α or peginterferon-α for hepatitis C.

A 51-year-old man with hepatitis C developed intermittenttremor while receiving a 36-week course of amantadine,ribavirin and peginterferon-α [route, dosage and time to onsetnot stated]. His tremor disappeared on completion of thecourse. Three years later, he developed bradykinesia,asymmetrical/unilateral tremor and rigidity compatible withParkinson’s disease. He was treated with amantadine,rasagiline and pramipexole [outcome not stated].

A 71-year-old man developed tremor after 8 weeks ofinterferon-α therapy [route and dosage not stated] forhepatitis C. His tremor resolved on completion of 48 weeks’therapy. He was commenced on ribavirin and peginterferon-α[route and dosage not stated] 2 years later due to treatmentfailure, with tremor, bradykinesia and rigidity appearing after24 weeks. His Parkinson’s disease progressed over 2 years,requiring treatment with levodopa/carbidopa [outcome notstated].

Author comment: "The association of [interferon-α] and[Parkinson’s disease] is important clinically andpathobiologically".Wangensteen KJ, et al. Interferon alpha treatment, hepatitis C andParkinson's disease. Movement Disorders 28: S295-S296, Jun 2013.Available from: URL: http://dx.doi.org/10.1002/mds.25605 - USA 803092058